First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients

Inclusion Criteria: * Participants must be listed for kidney transplantation, * AD cohort participants: First transplantation, Panel Reactive Antibody (PRA) \< 20%, negative Donor Specific Antibody (DSA), no anti-HLA antibodies, Epstein-Barr Virus positive (EBV+) serology, * TD cohort participants: First transplantation, 0-50 % PRA, negative DSA, negative flow cytometry crossmatch (FCXM) for any patients with anti-HLA antibodies on screening is mandatory, Epstein-Barr Virus positive (EBV+) serology * Participants must weigh at least 50 kg and have a Body Mass Index (BMI) 18.0 ≤ BMI \< 35.0 kg/m2, * White Blood Cells \> 3000/mm3, platelets \> 75000/mm3, * Female participants (WOCBP) must have a negative pregnancy test at screening and use a highly effective birth control until 90 days after the last administration of study drug, * Non-vasectomized male subjects having a female partner of childbearing potential must agree to the use of a highly effective method of contraception until 90 days after the last administration of study drug, * Participants must be capable of giving signed informed consent. Exclusion Criteria: * Patients with an active cancer or a history of kidney cancer, * Patients who have previously been exposed to other anti-lymphocyte globulins, * Patients with previous organ transplantation, * Patients with a history of specific viral infection that would contraindicate depleting antibody therapy (Hepatitis B and C, HIV), * Patients with a positive HIV and/o…